Relmada Therapeutics Inc To Host Investor Event Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Uy Ear - Mizuho - Analyst : Thanks, yeah, congrats on the data, guys. It seems like an exciting, technology. So, maybe our first question, we've been sort of getting from investors was sort of, I think people were kind of surprised by the small number of patients with CIS versus the larger number of patients with papillary. And so maybe just help us to understand, is it, was that just the nature of the site, the number of patients who went there, or was this by design, and why did you choose to pursue this route instead of, I think show datas that are sort of more cyst related as some of the other competitors have. Thanks.

Question: Uy Ear - Mizuho - Analyst : Okay. And if I can follow up, how do you sort of view the data relative to, some of the competing, the therapies like from J and JAR 200 and as well as the Credo, CGs, Credos, data that was presented as well this weekend.

Question: Uy Ear - Mizuho - Analyst : what's the safety as you expected, we see anything that's out of the ordinary or anything to that effect, at least based on what you seem to present, it seems fine with us, but just. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 28, 2025 / 8:30PM, RLMD.OQ - Relmada Therapeutics Inc To Host Investor Event

Question: Uy Ear - Mizuho - Analyst : And can I ask Doctor Loughton, follow-up question? Can you speak a bit about the community doctors and perhaps the need for efficiency, and how this could play into that? I think you mentioned some of that already. Just wanted to relative to the other therapies that will come to market or that's already on the market.

Question: Uy Ear - Mizuho - Analyst : Okay. Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 28, 2025 / 8:30PM, RLMD.OQ - Relmada Therapeutics Inc To Host Investor Event

Question: Andres Maldonado - HC Wainwright & Co. - Analyst : Hi guys, thank you for hosting this very helpful and thanks for taking my question. A few from us. Number one, over the years we've spoken to a number of urologists and have detected a true bifurcation of the original results that I guess were founded by Doctor Michael O'Donnell, who really started the gem Dosy kind of angle to treat NMIBC. So, the first question. Is what, for those neurologists that kind of are a little bit more skeptical on the geosy, regimen's place in NMIBC, what do you have to say to them to win them over and what are they missing? And then I have a few follow-ups.

Question: Andres Maldonado - HC Wainwright & Co. - Analyst : Sure, thank you, very helpful. And second question is, in a hypothetical, treatment landscape where retosimagine and TAR-200 are approved. Given that TAR-200 uses gemcitabine, what does that say for this product in terms of, is there a chance for re-sensitization given that there is, it's a combination with docetaxel and with a secondary chemotherapy and furthermore, Creusimagine announced, CG Oncology announced that Creusimagine will now be, studied in combination with, gemcitabine. Naturally, does this exclude these patient populations, and can you help us just fill the gaps to where you see the best fit in this scenario? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 28, 2025 / 8:30PM, RLMD.OQ - Relmada Therapeutics Inc To Host Investor Event

Question: Andres Maldonado - HC Wainwright & Co. - Analyst : Very helpful. And if I can ask another question, help us contextualize, where the pecking order of where this, therapy ranks in terms of ease of administration. We've heard a lot of companies spinning on their drugs saying that this is, this can be a plug and play into normal urology practices. I mean, given that this This is really a disease that is majorly treated by community urologists. I mean, I understand that the technology is supposed to aid in the helping of urologists being able to handle, a chemotherapy agent. Can you talk a little bit about where this ranks in terms of ease of administration is the question? Sure.

Question: Leland Gershell - Oppenheimer & Co. - Analyst : Oh, great. Good afternoon and thanks for these data and discussion and Doctor Lotan question for you here, maybe more kind of a mechanistic question and may relate to kind of sequencing down the road as these agents become available, but we're seeing in the high risks NMIBC space, sort of the immunotherapeutic approaches and then the chemotherapeutic approaches. One could argue that the chemo approaches may be, potentially, harmful or working against the immunotherapeutic approaches given that they may be, destroying some of the components of the immune system that that could be actively working to destroy a tumor. So just wondering if that Could affect how urologists may think about sequencing these agents, as, NDV-01 comes forward and then also of course the TAR-200, and so forth, and have a follow up. Thank you. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. APRIL 28, 2025 / 8:30PM, RLMD.OQ - Relmada Therapeutics Inc To Host Investor Event

Question: Leland Gershell - Oppenheimer & Co. - Analyst : Got it. And yeah, and for the Relmada team just curious, as this trial presumably continues, you'll have further follow up, should we, do we expect to see another interim from this trial later this year? Could that be at SUO or perhaps you don't, do you have insurance plans, yeah, just, curious. Thanks.

Question: Leland Gershell - Oppenheimer & Co. - Analyst : Great, thanks very much.